Vor Biopharma Inc. (VOR)
NASDAQ: VOR
· Real-Time Price · USD
0.68
0.02 (2.87%)
At close: May 02, 2025, 12:31 PM
2.87% (1D)
| Bid | n/a |
| Market Cap | 85.49M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -116.91M |
| EPS (ttm) | -1.7 |
| PE Ratio (ttm) | -0.4 |
| Forward PE | -0.76 |
| Analyst | Buy |
| Ask | n/a |
| Volume | 95,236 |
| Avg. Volume (20D) | 299,908 |
| Open | 0.69 |
| Previous Close | 0.66 |
| Day's Range | 0.67 - 0.69 |
| 52-Week Range | 0.49 - 1.87 |
| Beta | -0.21 |
About VOR
Vor Biopharma, Inc., a clinical-stage company, develops engineered hematopoietic stem cell (eHSC) therapies for cancer patients. It is developing VOR33, an eHSC product candidate that is in phase 1/2 to treat acute myeloid leukemia (AML) and other hematological malignancies. The company's VOR33 eHSCs lacks CD33, a protein that is expressed by AML blood cancer cells. The company's eHSCs targeted therapies, such as CAR-Ts, bispecific antibodies, an...
Industry Biotechnology
Sector Healthcare
IPO Date Feb 5, 2021
Employees 159
Stock Exchange NASDAQ
Ticker Symbol VOR
Website https://www.vorbio.com
Analyst Forecast
According to 7 analyst ratings, the average rating for VOR stock is "Buy." The 12-month stock price forecast is $11, which is an increase of 1506.54% from the latest price.
Stock Forecasts4 months ago
+51.55%
Vor Bio shares are trading higher after the compan...
Unlock content with
Pro Subscription
4 months ago
+26.89%
Vor Biopharma shares are trading higher after the company announced it will present data on its AML therapy at the ASH 2024 annual meeting.
